Multivariable logistic model of factors predicting pulmonary exacerbation during the first year of follow up
| Patient characteristic | Odds ratio (95% CI) | p value |
|---|---|---|
| FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BMI, body mass index. | ||
| Age | 0.93 (0.89 to 0.97) | 0.002 |
| Female sex | 1.37 (0.69 to 2.72) | 0.37 |
| BMI (kg/m2) | 0.92 (0.83 to 1.01) | 0.07 |
| Lung function | ||
| FEV1 (% predicted) | 0.97 (0.94 to 1.00) | 0.05 |
| FVC (% predicted) | 1.02 (0.99 to 1.05) | 0.14 |
| CF related diabetes mellitus | 0.81 (0.36 to 1.81) | 0.61 |
| Courses of IV antibiotics for pulmonary exacerbation in past 24 months | ||
| 0 | – | – |
| 1 | 2.30 (0.99 to 5.31) | 0.05 |
| 2–3 | 7.74 (2.94 to 20.39) | <0.0001 |
| >3 | 20.81 (6.37 to 67.92) | <0.0001 |
| <0.0001 (trend) | ||
| Bacteria in sputum at enrolment | ||
| Burkholderia cepacia complex (BC) | 0.96 (0.30 to 3.09) | 0.94 |
| Pseudomonas aeruginosa (PA) | 0.79 (0.25 to 2.47) | 0.68 |
| Both BC and PA | 0.63 (0.10 to 4.00) | 0.63 |
| Other | – | – |
| New bacterial species acquired in sputum during study | 0.50 (0.13 to 1.93) | 0.32 |
| Medications used chronically | ||
| Inhaled corticosteroid | 1.92 (1.00 to 3.71) | 0.05 |
| DNase | 1.24 (0.56 to 2.76) | 0.59 |
| Inhaled antibiotics | 1.46 (0.74 to 2.89) | 0.28 |
| Oral antibiotics | ||
| None | – | – |
| Azithromycin | 0.28 (0.11 to 0.72) | 0.01 |
| Other | 0.87 (0.31 to 2.46) | 0.79 |